Article Text

PDF

CASE REPORT
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam
  1. Prakash Peddi1,
  2. Nisha Elizabeth Ajit2,
  3. Gary Von Burton3,
  4. Hazem El-Osta1
  1. 1Louisiana State University Health Sciences Center Shreveport School of Medicine, Shreveport, Louisiana, USA
  2. 2Department of Internal Medicine, Louisiana State University Health Sciences Center Shreveport School of Medicine, Shreveport, Louisiana, USA
  3. 3Department of Hematology and Oncology, Louisiana State University Health Sciences Center Shreveport School of Medicine, Shreveport, Louisiana, USA
  1. Correspondence to Dr Prakash Peddi, ppeddi{at}lsuhsc.edu

Summary

Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14.6 months by maximal safe resection with radiation and temozolamide. In the absence of chemotherapy, radiotherapy or chemoradiotherapy, spontaneous regression of GBM or regression while only being on dexamethasone (DEX) and levetiracetam (LEV) have seldom been reported. Here, we present a case of a patient who had significant regression of the GBM with DEX and LEV alone. In this study, we hypothesise a plausible antineoplastic role of DEX and or LEV in GBM and highlight molecular, preclinical and clinical studies supporting this role.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors PP and NEA conceived and designed the manuscript, and also drafted the manuscript.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.